Mivacron (Mivacurium Chloride)

Mivacurium chloride acts by competitively binding to nicotinic acetylcholine receptors at the motor end‑plate of the neuromuscular junction. By blocking acetylcholine from activating these receptors, it prevents depolarization of the muscle membrane, thereby inhibiting transmission of nerve impulses and producing a reversible skeletal muscle relaxation. The effect is dose‑dependent and wears off as the drug is hydrolyzed by plasma cholinesterases.

The specific dose of Mivacron is determined by the prescribing anesthesiologist based on the patient’s age, weight, clinical condition, and the required depth of muscle relaxation. Dosing is individualized and administered intravenously as a bolus or infusion under continuous neuromuscular monitoring. The prescriber adjusts the amount to achieve the desired effect while minimizing the risk of prolonged paralysis.

Safety data for mivacurium chloride in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Because the drug crosses the placenta and may affect the fetus, it should only be used during pregnancy when the potential benefit justifies the potential risk. Use during breastfeeding is generally avoided unless the benefits outweigh possible risks to the infant.

To place an order, visit the product page for Mivacron on the GNH India website (gnhindia.com) and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Mivacron is a short‑acting, non‑depolarizing agent that is rapidly hydrolyzed by plasma cholinesterases, resulting in a relatively brief duration of action compared with longer‑acting agents such. Its rapid onset makes it useful for short procedures or for facilitating rapid sequence intubation, whereas other agents may be preferred when prolonged muscle relaxation is required. Choice of agent depends on surgical length, patient factors, and anesthetic plan.

Mivacron should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). The vial must be kept in its original packaging to protect it from light and moisture, and it must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration; discard if any abnormalities are observed. Follow local regulations for handling sterile injectable products.

Mivacron is supplied as a sterile injection solution for intravenous use. It is typically given as an initial bolus dose over a few seconds, followed by additional doses or a continuous infusion if longer muscle relaxation is needed. Administration is performed by a qualified anesthesiologist or trained medical professional in a controlled setting, such as an operating theatre, with continuous monitoring of neuromuscular function, blood pressure, and heart rate.

The most serious adverse reactions to Mivacron include anaphylaxis, prolonged apnea or respiratory paralysis, severe hypotension, bronchospasm, and cardiac arrhythmias. These events may require immediate airway management, administration of reversal agents, and supportive cardiovascular care. Patients with known hypersensitivity to mivacurium or other neuromuscular blocking agents should not receive the drug, and careful monitoring is essential to detect and treat serious complications promptly.

Mivacron is contraindicated in individuals with a documented hypersensitivity to mivacurium chloride or any component of the formulation. Caution is advised in patients with severe hepatic or renal impairment, as drug clearance may be reduced. It should also be avoided in patients receiving cholinesterase inhibitors that could prolong neuromuscular blockade, unless the benefits outweigh the risks and appropriate monitoring is in place.